Leukemia & Lymphoma Advanced Learning Center

This Advanced Learning Center covers breaking research and important clinical information for oncologists treating leukemia and lymphoma. 

FDA Approves Crizotinib for Younger ALK-Positive Anaplastic Large Cell Lymphoma Patients

Selinexor Approved for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Featured Content

Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

May 13, 2021
FDA Accepts Investigational New Drug Application for BAFF-R Targeting CAR-T Therapy

FDA Accepts Investigational New Drug Application for BAFF-R Targeting CAR-T Therapy

November 13, 2020
Pembrolizumab Improves PFS for Patients With Relapsed, Refractory Classical Hodgkin Lymphoma

Pembrolizumab Improves PFS for Patients With Relapsed, Refractory Classical Hodgkin Lymphoma

April 05, 2021
ASH Issues New Guidelines for Older AML Patients

ASH Issues New Guidelines for Older AML Patients

December 01, 2020
NCCN Adds Zanubrutinib to Guideline Recommendations for Patients With CLL, SLL

NCCN Adds Zanubrutinib to Guideline Recommendations for Patients With CLL, SLL

February 04, 2021
Brentuximab Vedotin Effective in Real-World Treatment of Patients With Relapsed, Refractory Hodgkin Lymphoma

Brentuximab Vedotin Effective in Real-World Treatment of Patients With Relapsed, Refractory Hodgkin Lymphoma

November 25, 2020
Acalabrutinib Approved for CLL Treatment in EU

Acalabrutinib Approved for CLL Treatment in EU

November 20, 2020
CAR-T Therapy Shows Promise as First-Line Treatment for Patients With High-Risk LBCL

CAR-T Therapy Shows Promise as First-Line Treatment for Patients With High-Risk LBCL

December 04, 2020

Breaking News

FDA Approves Loncastuximab Tesirine-lpyl for Large B Cell Lymphoma

FDA Approves Loncastuximab Tesirine-lpyl for Large B Cell Lymphoma

May 28, 2021
Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

May 13, 2021
Immunotherapy Combination Offers No Benefit in R/R Lymphoid Cancers

Immunotherapy Combination Offers No Benefit in R/R Lymphoid Cancers

May 04, 2021
Topical Calcineurin Inhibitors Prescribed for Atopic Dermatitis May Increase Lymphoma Risk

Topical Calcineurin Inhibitors Prescribed for Atopic Dermatitis May Increase Lymphoma Risk

April 13, 2021

Lymphoma Videos

FDA Approves Acalabrutinib for Treatment of CLL, SLL

FDA Approves Acalabrutinib for Treatment of CLL, SLL

April 14, 2020
Findings Show Imbalance Between Clinical and Real-World CLL Treatments with Idelalisib

Findings Show Imbalance Between Clinical and Real-World CLL Treatments with Idelalisib

April 14, 2020
European Commission Approves Venetoclax for Previously Untreated CLL

European Commission Approves Venetoclax for Previously Untreated CLL

April 14, 2020

Acute Myeloid Leukemia News

ASH 2020: CPX-351 Plus Venetoclax Effective for Patients With Relapsed/Refractory, Newly Diagnosed AML

ASH 2020: CPX-351 Plus Venetoclax Effective for Patients With Relapsed/Refractory, Newly Diagnosed AML

December 08, 2020
ASH Issues New Guidelines for Older AML Patients

ASH Issues New Guidelines for Older AML Patients

December 01, 2020
FDA Approves Onureg as Continuing Therapy for Adults with AML in Remission

FDA Approves Onureg as Continuing Therapy for Adults with AML in Remission

October 08, 2020
VIALE Trial Shows Benefits of Venetoclax in Older AML Patients

VIALE Trial Shows Benefits of Venetoclax in Older AML Patients

August 26, 2020

Test Your Knowledge

More Content

FDA Approves Loncastuximab Tesirine-lpyl for Large B Cell Lymphoma

FDA Approves Loncastuximab Tesirine-lpyl for Large B Cell Lymphoma

May 28, 2021
Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

Standard Radiation Superior to Low-Dose Alternative for Patients With Indolent Lymphomas

May 13, 2021
Immunotherapy Combination Offers No Benefit in R/R Lymphoid Cancers

Immunotherapy Combination Offers No Benefit in R/R Lymphoid Cancers

May 04, 2021
Topical Calcineurin Inhibitors Prescribed for Atopic Dermatitis May Increase Lymphoma Risk

Topical Calcineurin Inhibitors Prescribed for Atopic Dermatitis May Increase Lymphoma Risk

April 13, 2021
Pembrolizumab Improves PFS for Patients With Relapsed, Refractory Classical Hodgkin Lymphoma

Pembrolizumab Improves PFS for Patients With Relapsed, Refractory Classical Hodgkin Lymphoma

April 05, 2021
FDA Approves Umbralisib for Marginal Zone, Follicular Lymphomas

FDA Approves Umbralisib for Marginal Zone, Follicular Lymphomas

March 04, 2021
NCCN Adds Zanubrutinib to Guideline Recommendations for Patients With CLL, SLL

NCCN Adds Zanubrutinib to Guideline Recommendations for Patients With CLL, SLL

February 04, 2021
FDA Approves Crizotinib for Younger ALK-Positive Anaplastic Large Cell Lymphoma Patients

FDA Approves Crizotinib for Younger ALK-Positive Anaplastic Large Cell Lymphoma Patients

January 28, 2021
ASH 2020: CPX-351 Plus Venetoclax Effective for Patients With Relapsed/Refractory, Newly Diagnosed AML

ASH 2020: CPX-351 Plus Venetoclax Effective for Patients With Relapsed/Refractory, Newly Diagnosed AML

December 08, 2020
CAR-T Therapy Shows Promise as First-Line Treatment for Patients With High-Risk LBCL

CAR-T Therapy Shows Promise as First-Line Treatment for Patients With High-Risk LBCL

December 04, 2020
ASH Issues New Guidelines for Older AML Patients

ASH Issues New Guidelines for Older AML Patients

December 01, 2020
Brentuximab Vedotin Effective in Real-World Treatment of Patients With Relapsed, Refractory Hodgkin Lymphoma

Brentuximab Vedotin Effective in Real-World Treatment of Patients With Relapsed, Refractory Hodgkin Lymphoma

November 25, 2020
Acalabrutinib Approved for CLL Treatment in EU

Acalabrutinib Approved for CLL Treatment in EU

November 20, 2020
FDA Delays Review of Lisocabtagene Maraleucel for Lymphoma Due to COVID-19

FDA Delays Review of Lisocabtagene Maraleucel for Lymphoma Due to COVID-19

November 17, 2020
FDA Accepts Investigational New Drug Application for BAFF-R Targeting CAR-T Therapy

FDA Accepts Investigational New Drug Application for BAFF-R Targeting CAR-T Therapy

November 13, 2020
Pembrolizumab Improves Quality of Life in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Pembrolizumab Improves Quality of Life in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

November 03, 2020
FDA Clears Application for First Allogeneic CAR Gamma-Delta T Cell Therapy

FDA Clears Application for First Allogeneic CAR Gamma-Delta T Cell Therapy

October 31, 2020
FDA Approves Indication for Pembrolizumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

FDA Approves Indication for Pembrolizumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

October 27, 2020
FDA Accepts Supplemental Drug Application for Crizotinib as Pediatric Cancer Cell Treatment

FDA Accepts Supplemental Drug Application for Crizotinib as Pediatric Cancer Cell Treatment

October 23, 2020
Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines

Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines

October 20, 2020
FDA Approves Onureg as Continuing Therapy for Adults with AML in Remission

FDA Approves Onureg as Continuing Therapy for Adults with AML in Remission

October 08, 2020
Tafasitamab, Lenalidomide Improves Outcomes Over Monotherapy in Patients With Transplant-Ineligible DLBCL

Tafasitamab, Lenalidomide Improves Outcomes Over Monotherapy in Patients With Transplant-Ineligible DLBCL

October 02, 2020
VIALE Trial Shows Benefits of Venetoclax in Older AML Patients

VIALE Trial Shows Benefits of Venetoclax in Older AML Patients

August 26, 2020
NCCN Adds Tafasitamab to Clinical Practice Guidelines for Patients With Relapsed, Refractory DLBCL

NCCN Adds Tafasitamab to Clinical Practice Guidelines for Patients With Relapsed, Refractory DLBCL

August 26, 2020
Study Confirms the Most Effective Reduced-Intensity Conditioning Regimens

Study Confirms the Most Effective Reduced-Intensity Conditioning Regimens

August 11, 2020
Combination Ivosidenib, Venetoclax and Azacitidine Improves Overall Response in Patients with IDH1-Mutated AML

Combination Ivosidenib, Venetoclax and Azacitidine Improves Overall Response in Patients with IDH1-Mutated AML

August 10, 2020
Enasidenib Plus Azacytidine Significantly Improves CR, OR for Newly Diagnosed AML with IDH2 Mutations

Enasidenib Plus Azacytidine Significantly Improves CR, OR for Newly Diagnosed AML with IDH2 Mutations

August 10, 2020
Pembrolizumab Supplemental Biologics License Application Gets Priority Review From FDA

Pembrolizumab Supplemental Biologics License Application Gets Priority Review From FDA

July 29, 2020
Selinexor Approved for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Selinexor Approved for Relapsed or Refractory Diffuse Large B-cell Lymphoma

July 10, 2020
CD19 CAR NK-Cell Therapy Shows Strong Results for Leukemia and Lymphoma

CD19 CAR NK-Cell Therapy Shows Strong Results for Leukemia and Lymphoma

April 14, 2020
Combination of Ibrutinib and Venetoclax Helps Patients with Relapsed/Refractory CLL, Study Shows

Combination of Ibrutinib and Venetoclax Helps Patients with Relapsed/Refractory CLL, Study Shows

April 14, 2020
Study Findings Show Imbalance Between Clinical and Real-World CLL Treatment With Idelalisib

Study Findings Show Imbalance Between Clinical and Real-World CLL Treatment With Idelalisib

April 14, 2020
Phase 2 Trial Looked at Early Intervention Ibrutinib for Asymptomatic, High-Risk CLL Patients

Phase 2 Trial Looked at Early Intervention Ibrutinib for Asymptomatic, High-Risk CLL Patients

April 14, 2020
Rapid Escalation of Venetoclax Safe for Some Relapsed/Refractory CLL Patients

Rapid Escalation of Venetoclax Safe for Some Relapsed/Refractory CLL Patients

April 14, 2020
New CAR-T Results in 95% Response for Relapsed/Refractory Chronic Lymphocytic Leukemia

New CAR-T Results in 95% Response for Relapsed/Refractory Chronic Lymphocytic Leukemia

April 14, 2020
FDA Approves Acalabrutinib for Treatment of CLL, SLL

FDA Approves Acalabrutinib for Treatment of CLL, SLL

April 14, 2020
Findings Show Imbalance Between Clinical and Real-World CLL Treatments with Idelalisib

Findings Show Imbalance Between Clinical and Real-World CLL Treatments with Idelalisib

April 14, 2020
European Commission Approves Venetoclax for Previously Untreated CLL

European Commission Approves Venetoclax for Previously Untreated CLL

April 14, 2020